Published: February 2021
The anticipated growth in global diabetic patient population is likely to result in a significant rise in demand for novel, safe and more patient friendly drug delivery solutions for diabetics who are required to medicate on a frequent basis
Roots Analysis has announced the addition of “Diabetes Drug Delivery Devices Market, 2020-2030” report to its list of offerings.
Stakeholders engaged in this domain are presently focusing on introducing advanced features, such as integrated continuous glucose monitoring (CGM) systems, artificial intelligence (AI) enabled algorithms, provisions for audiovisual / tactile feedback, and automatic drug reconstitution features. Such efforts are primarily directed towards differentiating proprietary offerings within a highlight competitive market landscape, and are expected to drive the market’s growth over the coming years.
To order this 240+ page report, which features 50+ figures and 70+ tables, please visit this link
More than 80 diabetes drug delivery devices are presently available / under development
More than 65% of the aforementioned devices are marketed, while the rest are being evaluated in preclinical / clinical studies. It is also worth highlighting that majority of the drug delivery devices intended for diabetics are insulin pumps (35%), followed by pen injectors / autoinjectors (32%).
Over 50 companies, across the world, claim to be engaged in developing drug delivery devices for diabetics
Majority (44%) of the device developers are located in North America, primarily in the US. Within Europe, most of the developers are distributed across France, Germany, Switzerland, Italy and UK. Further, around 37% of the players engaged in this domain are large firms.
The market is dominated by the products of big pharma players
The leading pharmaceutical companies (in terms of number of products and revenues shares) involved in this domain are large / very large businesses. It is worth mentioning that the aforementioned players are investing significantly in terms of number of marketed and clinical-stage drugs, partnerships and strategic investments in this domain.
Partnership activity in this domain has grown at a CAGR of 33%, between 2015 and 2019
Maximum number of partnerships were reported in 2018. Majority of the agreements captured in the report, were observed to be related to technology integration deals (over 35%), followed by product development (16%).
North America and Europe are anticipated to capture over 60% of the overall market share by 2030
The current market is driven by the sales of diabetes drug delivery devices designed for subcutaneous administration (over 70%), followed by those that facilitate intravenous administration (26%). Further, pen injectors / autoinjectors currently capture 52% of the overall market share (in terms of sales revenues).
To request a sample copy / brochure of this report, please visit this link
The USD 31 million (by 2030) financial opportunity within the diabetes drug delivery devices market has been analyzed across the following segments:
The research covers detailed profiles of key players (listed below); each profile features an overview of the company, financial information (if available), details related to its technology portfolio, product portfolio, recent developments, and an informed future outlook.
For additional details, please visit
or email firstname.lastname@example.org
You may also be interested in the following titles:
1. Organ–based / Targeted Drug Delivery Devices Market for Biologics (Intra-organ / Intra-tumoral), 2020 - 2030
2. Global Handheld Ultrasound Imaging Devices Market, 2020-2030
3. Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices
4. Medical Device CROs Market (2nd Edition), 2020 – 2030
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry